Does Regence Cover Viagra? A Complete Insurance Guide

What Regence BlueCross BlueShield Is and How Its Formularies Work

Regence BlueCross BlueShield operates as a regional nonprofit insurer across four states: Oregon, Washington, Utah, and Idaho. The company administers dozens of distinct plan types, including individual marketplace plans, employer-sponsored group plans, Medicare Advantage plans, and Federal Employee Program (FEP) plans. Each plan carries its own formulary, which is the official list of covered drugs organized into cost-sharing tiers.

Why There Is No Single Regence Answer for Viagra

Because Regence administers so many distinct plans, there is no single formulary that applies to all members. A Regence Achieve plan purchased on Washington's individual marketplace may place generic sildenafil on Tier 2 with a $30 copay, while a self-funded employer plan administered by Regence could exclude ED medications entirely by the employer's choice. The 2024 Regence formulary for its most common commercial plans lists sildenafil (generic) under Tier 2 or Tier 3 with a prior-authorization requirement for the ED indication, while brand-name Viagra is listed as non-preferred or excluded on most commercial tiers.

How Drug Tiers Translate to Your Out-of-Pocket Cost

Most Regence commercial plans use a five-tier structure:

• Tier 1: Preferred generics (lowest copay, often $5, $15)
• Tier 2: Non-preferred generics and some preferred brands (copay $30, $50)
• Tier 3: Preferred brands (copay $50, $80)
• Tier 4: Non-preferred brands (copay $80, $150 or 40 to 50% coinsurance)
• Tier 5: Specialty drugs (typically 25 to 33% coinsurance)

Brand Viagra falls on Tier 3 or Tier 4 for most Regence commercial plans. Generic sildenafil most commonly lands on Tier 2, but the tier assignment can vary with the plan year refresh that occurs each January 1.

Erectile dysfunction affects approximately 30 million men in the United States, according to the National Institute of Diabetes and Digestive and Kidney Diseases [1]. The clinical and economic burden of ED is substantial, making insurance coverage a practical concern for millions of patients every year.

Does Regence Require Prior Authorization for Viagra or Sildenafil?

Yes. Prior authorization (PA) is required on most Regence commercial and Medicare Advantage plans before sildenafil will be covered for erectile dysfunction. The PA process exists because sildenafil is also FDA-approved for pulmonary arterial hypertension (PAH) under the brand name Revatio at a different dose (20 mg three times daily), and insurers use PA to confirm the drug is being prescribed for an insured indication at an appropriate dose.

What the Prior Authorization Process Involves

Your prescribing clinician submits a PA request to Regence that typically must document:

1. A confirmed diagnosis of erectile dysfunction (ICD-10 code N52.x)
2. The specific drug and dose being requested
3. Confirmation that the patient does not have a contraindication (such as concurrent nitrate use, which the FDA warns creates a risk of severe hypotension) [2]
4. In some plan years, documentation that the member tried a lower-cost alternative first (step therapy)

Regence is required under state law in Oregon, Washington, Utah, and Idaho to respond to urgent PA requests within 72 hours and standard requests within 5 business days. If the PA is denied, members have the right to appeal through Regence's internal appeals process and then through an independent external review.

Step Therapy Requirements

Some Regence plans include a step-therapy requirement for ED medications, meaning you must first try and fail a lower-cost option (typically generic sildenafil) before coverage of a brand-name PDE5 inhibitor like Cialis (tadalafil) or Stendra (avanafil) is authorized. Washington State's 2023 step therapy law (SB 5086) created additional patient protections around step therapy requirements for state-regulated plans, including the right to request a step-therapy exemption when clinically appropriate.

What the FDA Says About Sildenafil and Why It Matters for Coverage

The FDA approved sildenafil citrate (Viagra) in March 1998 for the treatment of erectile dysfunction in adult men [3]. The agency's approval was based on randomized controlled trial data showing that sildenafil produced statistically significant improvements in erectile function scores compared with placebo. In the key Phase III trials reviewed by the FDA, approximately 70% of men receiving sildenafil reported improved erections compared with approximately 22% on placebo [3].

Sildenafil works by selectively inhibiting phosphodiesterase type 5 (PDE5), which increases cyclic GMP in penile smooth muscle, allowing increased blood flow and erection in response to sexual stimulation. The FDA label specifies that sildenafil requires sexual stimulation to be effective and is not an aphrodisiac [3].

Because the FDA classifies Viagra as a treatment for a medical condition rather than a "lifestyle drug," it is theoretically coverable by insurance, unlike drugs classified purely for cosmetic or enhancement purposes. However, federal law does not require commercial insurers to cover ED medications, so Regence and other private insurers retain the right to exclude them from formularies or impose significant cost-sharing.

A 2021 analysis published in JAMA Internal Medicine found that among large employer plans, fewer than 50% covered any PDE5 inhibitor without restriction [4]. Generic sildenafil's availability since December 2017 has changed the calculus for many plans, making coverage more common for the generic than for brand Viagra.

How to Check Whether Your Specific Regence Plan Covers Viagra or Sildenafil

Step 1: Locate Your Formulary

Log in to your Regence member account at regence.com and manage to "My Plan" then "Prescription Drug List." Download the current-year formulary PDF or use the online drug search tool. Enter "sildenafil" and separately enter "Viagra" to see the tier placement, any PA requirements, and any quantity limits that apply to your specific plan.

Step 2: Read Your Evidence of Coverage

Your Evidence of Coverage (EOC) document contains a section titled "Prescription Drug Benefits" or "Exclusions and Limitations." Some Regence plans contain an explicit exclusion for "drugs used to treat sexual dysfunction or erectile dysfunction," which means no tier placement and no PA pathway can reveal coverage. If you see this exclusion, coverage is not available under that plan for ED medications.

Step 3: Call Regence Member Services

Call the number on the back of your Regence member ID card and ask specifically: "Is sildenafil for erectile dysfunction covered under my plan, and if so, what tier and what PA criteria apply?" Document the representative's name, date, and the reference number for the call.

Step 4: Ask Your Pharmacist to Run a Test Claim

A pharmacist can run a test claim before you fill the prescription, which will show the exact cost-sharing you will owe and whether a PA is required. This costs nothing and takes about two minutes.

Regence Medicare Advantage Plans and Viagra Coverage

Medicare Part D, which covers outpatient prescription drugs, explicitly excludes drugs "used for the treatment of sexual or erectile dysfunction" under 42 CFR 423.120(b)(5) unless the drug is also approved for another condition covered by Part D [5]. This means that for standard Medicare Part D plans, sildenafil at ED doses (25 mg, 50 mg, 100 mg) is excluded.

The Revatio Exception

Sildenafil 20 mg (brand name Revatio) is FDA-approved for pulmonary arterial hypertension. Medicare Part D plans, including Regence Medicare Advantage Rx plans, are permitted to cover Revatio for the PAH indication. If a clinician prescribes 20 mg three times daily for a documented PAH diagnosis, coverage may be available even under a Medicare plan. Prescribing sildenafil at ED doses under a PAH diagnosis to circumvent coverage rules is fraudulent and places both the patient and prescriber at legal risk [5].

Regence Medicare Advantage Formulary Specifics

Regence Medicare Advantage plans for 2024 and 2025 follow the CMS exclusion for ED indications. Members with both ED and PAH should work with their pulmonologist and Regence to manage the Revatio benefit separately from any ED management.

Generic Sildenafil: The Most Practical Coverage and Cost Path

Generic sildenafil became widely available in the United States in December 2017 after Pfizer's exclusivity agreement with Teva Pharmaceuticals took effect [6]. Today, more than a dozen manufacturers produce generic sildenafil citrate tablets in 20 mg, 25 mg, 50 mg, and 100 mg strengths.

Cost Without Insurance

Without any insurance benefit, generic sildenafil retails for approximately $1 to $3 per tablet at major pharmacy chains when purchased with a GoodRx or similar discount card. Brand-name Viagra remains $40 to $60 per tablet without insurance assistance. The price differential is substantial: a 30-tablet supply of generic sildenafil 50 mg at GoodRx prices typically runs $30 to $60, while the same quantity of brand Viagra exceeds $400 at retail.

Cost With Regence Coverage

When generic sildenafil is on Tier 2 of a Regence commercial plan and PA is approved, the member copay is typically $30 to $50 for a 30-day supply. On Tier 3, copays range from $50 to $80. Some plans impose a quantity limit of 6 or 8 tablets per 30 days rather than covering a full 30-tablet supply, reflecting guidance from some PBMs (pharmacy benefit managers) that aligns with standard clinical dosing of one tablet per sexual event.

A 2020 study in the American Journal of Men's Health found that out-of-pocket cost was the leading reason men did not fill ED prescriptions, with 38% of men citing cost as a primary barrier [7]. Generic sildenafil has reduced but not eliminated this barrier for men without adequate insurance coverage.

Clinical Effectiveness: What the Evidence Shows

Sildenafil's effectiveness for erectile dysfunction is well-established across multiple populations. The STEP-1 equivalent in ED pharmacology is the original Pfizer Phase III program: across four randomized, double-blind, placebo-controlled trials (combined N=approximately 1,400), sildenafil at doses of 25 mg, 50 mg, and 100 mg produced International Index of Erectile Function (IIEF) domain scores significantly above placebo at 12 to 24 weeks, with 70% of sexual attempts successful on sildenafil versus 22% on placebo [3].

Sildenafil in Men with Diabetes

Erectile dysfunction is approximately three times more common in men with type 2 diabetes than in the general population, according to a systematic review in Diabetic Medicine [8]. In men with diabetes-associated ED, sildenafil 100 mg improved IIEF scores by a mean of 7.4 points above placebo in a dedicated randomized trial (N=268), with 61% of patients reporting improved erections versus 22% on placebo [8].

Cardiovascular Safety Considerations

The FDA label carries a contraindication against co-administration of sildenafil with any organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) due to the risk of severe, potentially fatal hypotension [2]. Men taking alpha-blockers should be counseled about additive hypotensive effects. The Princeton Consensus (Third Princeton Consensus Conference on Sexual Activity and Cardiac Risk) provides a structured approach to risk stratification for ED treatment in men with cardiovascular disease, categorizing patients into low, intermediate, and high risk before initiating PDE5 inhibitor therapy [9].

The American Heart Association has stated that "sexual activity is acceptable for most patients with stable cardiovascular disease" and that PDE5 inhibitors are appropriate for low- and intermediate-risk patients after appropriate evaluation [9]. This clinical guidance supports the medical legitimacy of ED treatment and, by extension, the case for insurance coverage.

Comparing PDE5 Inhibitors Available in the United States

| Drug | Onset | Duration | Typical Dose | Generic Available | |---|---|---|---|---| | Sildenafil (Viagra) | 30 to 60 min | 4 to 6 hrs | 50 mg as needed | Yes (since 2017) | | Tadalafil (Cialis) | 30 to 45 min | Up to 36 hrs | 10 mg as needed or 2.5 to 5 mg daily | Yes (since 2018) | | Vardenafil (Levitra) | 25 to 60 min | 4 to 5 hrs | 10 mg as needed | Yes | | Avanafil (Stendra) | 15 to 30 min | 6 to 12 hrs | 100 mg as needed | No |

All four agents work through PDE5 inhibition. Tadalafil's longer half-life (17.5 hours) supports once-daily dosing at 5 mg, which some Regence plans cover when documented for benign prostatic hyperplasia (BPH) as well as ED under a dual-indication strategy.

What to Do If Regence Denies Coverage for Viagra or Sildenafil

File a Formal Appeal

If your PA request is denied, request a written denial notice with the specific clinical criteria that were not met. Under the Affordable Care Act, all non-grandfathered commercial plans must provide an internal appeal process and access to independent external review. Submit your appeal with a letter from your clinician explaining the medical necessity of the prescribed dose and formulation. A 2019 analysis in Health Affairs found that patients who appealed insurance denials succeeded in overturning denials approximately 39% to 59% of the time depending on the type of coverage dispute [10].

Use a Manufacturer Coupon or Patient Assistance Program

Pfizer offers a Viagra savings program for commercially insured patients. The program does not apply to Medicare, Medicaid, or VA-covered patients. Generic manufacturers generally do not offer copay cards, but discount programs such as GoodRx, RxSaver, and Cost Plus Drugs (Mark Cuban's cost-plus pharmacy) may reduce out-of-pocket cost below your insurance copay for generic sildenafil.

Consider Telehealth Prescribing for Cost Efficiency

Telehealth prescribing platforms, including HealthRX-affiliated clinicians, can evaluate ED, prescribe sildenafil or tadalafil where clinically appropriate, and direct prescriptions to pharmacies with the most competitive cash pricing. For men whose Regence plan excludes ED medications entirely, paying cash for generic sildenafil at a discount pharmacy may cost less than an in-person specialist visit plus a denied insurance claim.

Request a Formulary Exception

If your plan places brand Viagra in an excluded or non-preferred tier but your clinician documents a medical reason why generic sildenafil is not appropriate (for example, a documented allergy to a generic's inactive ingredient), you may request a formulary exception. Regence's formulary exception process requires clinician documentation and is evaluated by the plan's pharmacy and therapeutics committee. Exceptions are granted infrequently but are a legitimate recourse when clinical circumstances justify them.

Regence FEP (Federal Employee Program) Coverage for Viagra

Federal employees covered under the Federal Employee Health Benefits (FEHB) program through Regence FEP are subject to a different formulary than commercial Regence members. The Regence FEP Blue Cross Blue Shield plan has historically covered generic sildenafil on its formulary for ED, typically on Tier 2 or Tier 3 with PA requirements. The Office of Personnel Management (OPM), which administers FEHB, requires that plans offer coverage for ED medications to federal employees when medically necessary and prescribed for a covered indication. Federal employees should review the current-year Regence FEP brochure, published annually by OPM, for exact tier placement and PA criteria.

State-Level Mandates That Affect Regence Coverage

Oregon, Washington, Utah, and Idaho do not currently have state insurance mandates requiring coverage of erectile dysfunction medications on commercial formularies. This contrasts with mandates in some states for other sexual health treatments. Because Regence primarily operates in these four states, no state mandate currently compels Regence commercial plans to cover Viagra or generic sildenafil. However, self-funded employer plans are governed by federal ERISA law rather than state insurance law, which means state mandates do not apply to them at all regardless of which state the employee works in.

The Relationship Between ED and Underlying Health Conditions

Erectile dysfunction is frequently a marker of systemic vascular disease. A landmark prospective cohort study published in JAMA (Thompson et al., N=9,457 men in the Prostate Cancer Prevention Trial) found that new-onset ED was associated with a 25% increased risk of subsequent cardiovascular events over a median 5.1-year follow-up [11]. This association means that a clinical evaluation for ED should include assessment for hypertension, dyslipidemia, diabetes, and other cardiovascular risk factors.

When Regence or another insurer requires PA for sildenafil, the process ideally prompts this broader clinical evaluation. A thorough PA submission that includes cardiovascular risk assessment, testosterone level (since hypogonadism affects ED in approximately 10% to 15% of men with ED) [12], and documentation of the diagnostic workup may strengthen the medical necessity argument and increase the likelihood of approval.

Testosterone deficiency is independently associated with reduced response to PDE5 inhibitors. A 2014 meta-analysis in the Journal of Sexual Medicine (N=303 across 7 trials) found that combination therapy with testosterone replacement plus a PDE5 inhibitor improved IIEF scores more than either agent alone in men with hypogonadism and ED [12]. If a Regence member has both hypogonadism and ED, separate PA pathways for testosterone replacement therapy (TRT) and sildenafil may each be pursued.

Practical Prescribing Guidance From Clinical Guidelines

The American Urological Association (AUA) 2018 guideline on erectile dysfunction states: "Phosphodiesterase type 5 inhibitors are recommended as first-line therapy for erectile dysfunction in the absence of contraindications." The guideline also specifies that clinicians should counsel patients on the need for sexual stimulation, the different onset and duration profiles of available agents, and the importance of dose titration starting at 50 mg for sildenafil [13].

The Endocrine Society's 2010 guideline on male hypogonadism, updated in subsequent clinical practice guidance, recommends evaluating men with ED for testosterone deficiency and treating hypogonadism before or concurrently with PDE5 inhibitor therapy when both conditions are present [14]. This two-pronged approach may require separate PA submissions to Regence: one for testosterone replacement and one for sildenafil.

For men with diabetes and ED, the American Diabetes Association (ADA) Standards of Care include evaluation and management of sexual dysfunction as part of comprehensive diabetes care, noting that "sexual dysfunction in men with diabetes should be treated with lifestyle modification, optimization of glycemic and cardiovascular risk factor control, and pharmacotherapy with PDE5 inhibitors as first-line agents" [15].